Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867006700774490113 |
|---|---|
| author | Kentaro Iwata Shunkichi Ikegaki Yoji Hyodo Hideaki Miyake |
| author_facet | Kentaro Iwata Shunkichi Ikegaki Yoji Hyodo Hideaki Miyake Kentaro Iwata Shunkichi Ikegaki Yoji Hyodo Hideaki Miyake |
| collection | Wiley Open Access |
| contents | Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference Kentaro Iwata Shunkichi Ikegaki Yoji Hyodo Hideaki Miyake Clinical Transplantation ABSTRACT Objectives Hepatitis B vaccination is recommended for those receiving kidney transplants. When hepatitis B surface antibody (HBsAb) levels remain low, the booster dose of the vaccine should be considered. Some consider that the use of a different product as a booster might be beneficial to the patients, but the effectiveness of such a strategy has not been evaluated. Methods The kidney transplant recipients (KTR) who received hepatitis B vaccines (Bimmugen or Heptavax‐II), and failed to develop enough antibody titer and those who received additional vaccines, were enrolled in the study. Those who received a different product were compared with those who received the same product as the booster. The outcome is the seroconversion of hepatitis B surface antibody level ≧ 10 IU/mL. Results A total of 26 patients were non‐responders after a receipt of three‐dose hepatitis B vaccines. Among those, 15 received additional hepatitis B vaccine of the different product (crossover group), and 11 received the same product (non‐crossover group). Only five patients (19.2%) had seroconversion after the booster doses, three in the crossover group (20%) and two in the non‐crossover group (18.2%) ( p = 1.0). In the Bayesian analysis, the medial posterior probability of the seroconversion rate of the crossover group was 23% (95% CrI: 7%–47%), whereas that of the non‐crossover group was 14% (95% CrI: 2%–40%). Conclusion The crossover strategy hepatitis B vaccines did not appear to lead to seroconversion of much significance among KTR. Other options to augment the protection should be investigated to protect these populations against the infection. 10.1111/ctr.70307 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| doi_str_mv | 10.1111/ctr.70307 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_70307 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference Kentaro Iwata Shunkichi Ikegaki Yoji Hyodo Hideaki Miyake Clinical Transplantation Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference Kentaro Iwata Shunkichi Ikegaki Yoji Hyodo Hideaki Miyake Clinical Transplantation ABSTRACT Objectives Hepatitis B vaccination is recommended for those receiving kidney transplants. When hepatitis B surface antibody (HBsAb) levels remain low, the booster dose of the vaccine should be considered. Some consider that the use of a different product as a booster might be beneficial to the patients, but the effectiveness of such a strategy has not been evaluated. Methods The kidney transplant recipients (KTR) who received hepatitis B vaccines (Bimmugen or Heptavax‐II), and failed to develop enough antibody titer and those who received additional vaccines, were enrolled in the study. Those who received a different product were compared with those who received the same product as the booster. The outcome is the seroconversion of hepatitis B surface antibody level ≧ 10 IU/mL. Results A total of 26 patients were non‐responders after a receipt of three‐dose hepatitis B vaccines. Among those, 15 received additional hepatitis B vaccine of the different product (crossover group), and 11 received the same product (non‐crossover group). Only five patients (19.2%) had seroconversion after the booster doses, three in the crossover group (20%) and two in the non‐crossover group (18.2%) ( p = 1.0). In the Bayesian analysis, the medial posterior probability of the seroconversion rate of the crossover group was 23% (95% CrI: 7%–47%), whereas that of the non‐crossover group was 14% (95% CrI: 2%–40%). Conclusion The crossover strategy hepatitis B vaccines did not appear to lead to seroconversion of much significance among KTR. Other options to augment the protection should be investigated to protect these populations against the infection. 10.1111/ctr.70307 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title | Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70307 |